Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer.
Authors
D'Amico, Anthony VChen, Ming-Hui
Crook, Juanita
Armstrong, John G
Malone, Shawn
Steigler, Allison
Dunne, Mary
Kantoff, Philip W
Denham, James W
Affiliation
Brigham and Women's Hospital, Boston, MA 02115, USA. adamico@partners.orgIssue Date
2011-12-10MeSH
AgedAndrogen Antagonists
Antineoplastic Agents, Hormonal
Cohort Studies
Combined Modality Therapy
Humans
Male
Neoplasm Staging
Prognosis
Prostatic Neoplasms
Treatment Outcome
Metadata
Show full item recordCitation
Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer. 2011, 29 (35):4682-7 J. Clin. Oncol.Journal
Journal of clinical oncology : official journal of the American Society of Clinical OncologyDOI
10.1200/JCO.2011.37.0726PubMed ID
22042952Abstract
We evaluated whether the duration of androgen suppression therapy (AST) had an impact on the risk of prostate cancer-specific mortality (PCSM) in men with unfavorable-risk prostate cancer (PC) within established Gleason score (GS) categories.Item Type
ArticleLanguage
enISSN
1527-7755ae974a485f413a2113503eed53cd6c53
10.1200/JCO.2011.37.0726
Scopus Count
Collections
Related articles
- Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
- Authors: Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV
- Issue date: 2010 Apr
- Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy.
- Authors: D'Amico AV, Renshaw AA, Loffredo B, Chen MH
- Issue date: 2007 Oct 15
- Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer.
- Authors: Rosenberg JE, Chen MH, Nguyen PL, Braccioforte MH, Moran BJ, D'Amico AV
- Issue date: 2012 Mar
- Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
- Authors: D'Amico AV, Loffredo M, Renshaw AA, Loffredo B, Chen MH
- Issue date: 2006 Sep 1
- Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
- Authors: Tsai HK, Chen MH, McLeod DG, Carroll PR, Richie JP, D'Amico AV
- Issue date: 2006 Dec 1